Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bhaskar Dasgupta

Showing results (171-180 of 204) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|June 3, 2026
Phase 3 Trial of Secukinumab in Polymyalgia RheumaticaJohn H Stone, Frank Buttgereit, Alain Saraux, et al.
Annals of the Rheumatic Diseases|July 5, 2019
2018 Update of the EULAR recommendations for the management of large vessel vasculitisBernhard Hellmich, Ana Agueda, Sara Monti, et al.
Annals of the Rheumatic Diseases|March 3, 2016
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Johannes W J Bijlsma, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndromeJulia L Newton, James Frith, Danielle Powell, et al.
Annals of the Rheumatic Diseases|June 14, 2013
Health-related utility values of patients with primary Sjögren's syndrome and its predictorsDennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Annals of the Rheumatic Diseases|August 7, 2023
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 updateChristian Dejaco, Sofia Ramiro, Milena Bond, et al.
Swiss Medical Weekly|February 15, 2018
Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome RegistryAlexandre Dumusc, Wan-Fai Ng, Katherine James, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Rheumatology (Oxford, England)|September 22, 2014
Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?Dennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
The Journal of Rheumatology|July 3, 2018
Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability ExercisesValentin S Schäfer, Stavros Chrysidis, Christian Dejaco, et al.
Pageof 21

Showing results (171-180 of 204) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|June 3, 2026
Phase 3 Trial of Secukinumab in Polymyalgia RheumaticaJohn H Stone, Frank Buttgereit, Alain Saraux, et al.
Annals of the Rheumatic Diseases|July 5, 2019
2018 Update of the EULAR recommendations for the management of large vessel vasculitisBernhard Hellmich, Ana Agueda, Sara Monti, et al.
Annals of the Rheumatic Diseases|March 3, 2016
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Johannes W J Bijlsma, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndromeJulia L Newton, James Frith, Danielle Powell, et al.
Annals of the Rheumatic Diseases|June 14, 2013
Health-related utility values of patients with primary Sjögren's syndrome and its predictorsDennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Annals of the Rheumatic Diseases|August 7, 2023
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 updateChristian Dejaco, Sofia Ramiro, Milena Bond, et al.
Swiss Medical Weekly|February 15, 2018
Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome RegistryAlexandre Dumusc, Wan-Fai Ng, Katherine James, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Rheumatology (Oxford, England)|September 22, 2014
Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?Dennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
The Journal of Rheumatology|July 3, 2018
Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability ExercisesValentin S Schäfer, Stavros Chrysidis, Christian Dejaco, et al.
Pageof 21